Magenta Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Hey, good morning, everyone. My name is Daniel Wolle. I'm one of the analysts covering SMID-cap biotech. We're continuing the 40th Annual JPM Healthcare Conference with Magenta Therapeutics. It's my pleasure to introduce CEO and President, Jason Gardner. He will be doing presentations first, followed by Q&A. (Operator Instructions)
Without further ado, Jason?
Good morning, everyone, and thank you to JPMorgan for the opportunity to present our progress and plans at Magenta towards transforming stem cell transplant as a curative therapy for patients battling blood cancers, genetic diseases and autoimmune diseases.
Magenta is a unique clinical-stage biotech, and I'm excited to share our story, especially coming off a productive year for the portfolio in 2021. We will dive into our programs and focus on the plans for the coming year.
On the next slide is our disclosure statement
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
